FDG-PET in the management of germ cell tumor

Annals of Oncology

Volumn 16, Issue SUPPL. 4, 2005, Pages

  De Giorgi, Ugo ^a   Pupi, A ^b   Fiorentini, G ^a   Rosti, G ^c   Marangolo, M ^c  

^a ISTITUTO TOSCANO TUMORI   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SANTA MARIA DELLE CROCI HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; CARBON 11; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; FLUORINE 18; FLUORODEOXYGLUCOSE F 18; LACTATE DEHYDROGENASE; TUMOR MARKER;

ARTICLE; CANCER STAGING; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; GERM CELL TUMOR; HUMAN; MALE GENITAL SYSTEM SURGERY; MALIGNANT NEOPLASTIC DISEASE; MINIMAL RESIDUAL DISEASE; NON SEMINOMATOUS GERMINOMA; POSITRON EMISSION TOMOGRAPHY; PREDICTION; PRIORITY JOURNAL; SALVAGE THERAPY; SEMINOMA; TESTIS TERATOMA; TREATMENT OUTCOME; TUMOR RECURRENCE;

ADULT; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MEDIASTINAL NEOPLASMS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEOPLASMS, GERM CELL AND EMBRYONAL; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RETROPERITONEAL NEOPLASMS; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 30644456948     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdi915     Document Type: Article

References (39)

1. Gori S, Porrozzi S, Roila et al. Germ cell tumours of the testis. Crit Rev Oncol Hematol 2005; 53: 141-164.
2. Sonneveld DJ, Hoekstra HJ, van der Graaf WT et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 2001; 91: 1304-1315.
3. International Germ Cell Cancer Collaborative Group. International Germ Cell Consensus Classification: A prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
4. Shvarts O, Han K, Seltzer M, Pantuck AJ, Belldegrun AS. Positron emission tomography in urologic oncology. Cancer Control 2002; 9: 335-342.
5. Schmoll HJ, Souchon R, Krege S et al. European consensus on diagnosis and treatment of germ cell cancer: A report of the European Germ Cell Cancer Consensus Group (EGCCCG). Ann Oncol 2004; 15: 1179-1200.
6. Harvey ML, Geldart TR, Duell R, Mead GM, Tung K. Routine computerised tomographic scans of the thorax in surveillance of stage I testicular non-seminomatous germ-cell cancer-a necessary risk? Ann Oncol 2002; 13: 237-242.
7. Vergouwe Y, Steyerberg EW, Eijkemans MJ, Albers P, Habbema JD. Predictors of occult metastasis in clinical stage I nonseminoma: A systematic review. J Clin Oncol 2003; 21: 4092-4099.
8. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Harper PG, Huddart RA. Fluorodeoxyglucose positron emission tomography in the evaluation of germ cell tumours at relapse. Br J Cancer 2000; 83: 863-869.
9. Spermon JR, De Geus-Oei LF, Kiemeney LA, Witjes JA, Oyen WJ. The role of (18)-fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ. cell tumours. Brit J Urol Int 2002; 89: 549-556.
10. Tsatalpas P, Beuthien-Baumann B, Kropp J et al. Diagnostic value of 18F-FDG positron emission tomography for detection and treatment control of malignant germ cell tumors. Urol Int 2002; 68: 157-163.
11. Hain SF, O'Doherty MJ, Timothy AR, Leslie MD, Partridge SE, Huddart RA. Fluorodeoxyglucose PET in the initial staging of germ cell tumours. Eur J Nucl Med 2000; 27: 590-594.
12. Albers P, Bender H, Yilmaz H, Schoeneich G, Biersack HJ, Mueller SC. Positron emission tomography in the clinical staging of patients with Stage I and II testicular germ cell tumors. Urology 1999; 53: 808-811.
13. National Cancer Institute Clinical Trials. Available from: http://www.nci.nih.gov/search/ViewClinicalTrialsaspx?cdrid= 256314&version=patient&protocolsearchid=1434689
14. Sanchez D, Zudaire JJ, Fernandez JM et al. 18F-fluoro-2-deoxyglucose-positron emission tomography in the evaluation of nonseminomatous germ cell tumours at relapse. Brit J Urol Int 2002; 89: 912-916.
15. Maszelin P, Lumbroso J, Theodore C, Foehrenbach H, Merlet P, Syrota A. Fluorodeoxyglucose (FDO) positron emission tomography (PET) in testicular germ cell tumors in adults: Preliminary French clinical evaluation, development of the technique and its clinical applications. Prog Urol 2000; 10: 1190-1199.
16. Jerusalem G, Hustinx R, Beguin Y, Fillet G. The value of positron emission tomography (PET) imaging in disease staging and therapy assessment. Ann Oncol 2002; 13 (Suppl 4): 227-234.
17. Karapetis CS, Strickland AH, Yip D, van der Walt JD, Harper PG. PET and LAP in suspected testicular cancer relapse: Beware sarcoidosis. Ann Oncol 2001; 12: 1485-1488.
18. Rayon D, Burch PA, Richardson RL. Sarcoidosis and testicular carcinoma. Cancer 1998; 83: 361-361.
19. Patel PM, Alibazoglu H, Ali A, Fordham E, LaMonica G. Normal thymic uptake of FDG on PET imaging. Clin Nucl Med 1996; 21: 772-775.
20. Jerusalem G, Beguin Y, Fassotte MF et al. Early detection of relapse by whole-body positron emission tomography in the follow-up of patients with Hodgkin's disease. Ann Oncol 2003; 14: 123-130.
21. Couturier O, Luxen A, Chatal JF, Vuillez JP, Rigo P, Hustinx R. Fluorinated tracers for imaging cancer with positron emission tomography. Eur J Nucl Med Mol Imaging 2004; 31: 1182-1206.
22. Fizazi K, Culine S, Kramar A et al. Early predicted time to normalization of tumor markers predicts outcome in poor-prognosis nonseminomatous germ cell tumors. J Clin Oncol 2004; 22: 3868-3876.
23. Bokemeyer C, Kollmannsberger C, Oechsle K et al. Early prediction of treatment response to high-dose salvage chemotherapy in patients with relapsed germ cell cancer using [(18)F]FDG PET. Br J Cancer 2002; 86: 506-511.
24. De Santis M, Pont J. The role of positron emission tomography in germ cell cancer. World J Urol 2004; 22: 41-46.
25. Barthel H, Cleij MC, Collingridge DR et al. 3′-deoxy-3′-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003; 63: 3791-3798.
26. Zagars GK, Ballo MT, Lee AK, Strom SS. Mortality after cure of testicular seminoma. J Clin Oncol 2004; 22: 640-647.
27. Hanks GE, Peters T, Owen J. Seminoma of the testis: Long-term beneficial and deleterious results of radiation. Int J Radiat Oncol Biol Phys 1992; 24: 913-919.
28. Ganjoo KN, Chan RJ, Sharma M, Einhorn LH. Positron emission tomography scans in the evaluation of postchemotherapy residual masses in patients with seminoma. J Clin Oncol 1999; 17: 3457-3460.
29. 18Fluoro-2-Deoxy-D-Glucose Positron Emission Tomography for Residual Postchemotherapy Masses in Patients With Bulky Seminoma. J Clin Oncol 2001; 19: 3740-3744.
30. De Santis M, Becherer A, Bokemeyer C et al. 2-18fluoro-deoxy-D-glucose positron emission tomography is a reliable predictor for viable tumor in postchemotherapy seminoma: An update of the prospective multicentric SEMPET trial. J Clin Oncol 2004; 22: 1034-1039.
31. Pfannenberg AC, Oechsle K, Bokemeyer C et al. The role of [(18)F] FDG-PET, CT/MRI and tumor marker kinetics in the evaluation of post chemotherapy residual masses in metastatic germ cell tumors-prospects for management. World J Urol 2004; 22: 132-139.
32. Putra LJ, Lawrentschuk N, Ballok Z et al. 18F-fluorodeoxyglucose positron emission tomography in evaluation of germ cell tumor after chemotherapy. Urology 2004; 64: 1202-1207.
33. Karapetis CS, Strickland AH, Yip D, Steer C, Harper PG. Use of fluorodeoxyglucose positron emission tomography scans in patients with advanced germ cell tumour following chemotherapy: Single-centre experience with long-term follow up. Intern Med J 2003; 33: 427-435.
34. Kollmannsberger C, Oechsle K, Dohmen BM et al. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma. Cancer 2002; 94: 2353-2362.
35. Hartmann JT, Schmoll HJ, Kuczyk MA, Candelaria M, Bokemeyer C. Postchemotherapy resections of residual masses from metastatic non-seminomatous testicular germ cell tumors. Ann Oncol 1997; 8: 531-538.
36. Nuutinen JM, Leskinen S, Elomaa I et al. Detection of residual tumours in postchemotherapy testicular cancer by FDG-PET. Eur J Cancer 1997; 33: 1234-1241.
37. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in post-chemotherapy germ cell tumor patients. J Clin Oncol 1996; 14: 1637-1641.
38. Wilson CB, Young HE, Ott RJ et al. Imaging metastatic testicular germ cell tumours with 18FDG positron emission tomography: Prospects for detection and management. Eur J Nucl Med 1995; 22: 508-513.
39. Sugawara Y, Zasadny KR, Grossman HB et al. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology 1999; 211: 249-256.